Omeprazole and ranitidine

NEW YORK, July 31 (Praxis Press) Previous studies have shown that omeprazole sodium is more effective than ranitidine hydrochloride in controlling symptoms of heartburn in patients with gastroesophageal reflux disease (GERD). However, it is not clear whether these findings can be extrapolated to primary care practice. To compare the two medications, Kaplan-Machlis and colleagues performed a multicenter, randomized, open-label, medical effectiveness trial in 268 patients with GERD randomly assign

August 2, 2000

NEW YORK, July 31 (Praxis Press) Previous studies have shown that omeprazole sodium is more effective than ranitidine hydrochloride in controlling symptoms of heartburn in patients with gastroesophageal reflux disease (GERD). However, it is not clear whether these findings can be extrapolated to primary care practice. To compare the two medications, Kaplan-Machlis and colleagues performed a multicenter, randomized, open-label, medical effectiveness trial in 268 patients with GERD randomly assigned to receive omeprazole sodium or ranitidine hydrochloride for up to 6 months. The researchers assessed the status of the patients with the Gastrointestinal Symptom Rating Scale (GSRS) Reflux score, Psychological General Well-Being Index, and Short-Form-36 Health Survey at baseline and 2, 4, 12 and 24 weeks. Medical resource use and cost data were also collected. They found that more omeprazole-treated patients reported improved heartburn resolution at two weeks and four weeks compared with ranitidine-treated patients. Omeprazole provided greater resolution of heartburn symptoms at two and four weeks. Despite omeprazole's higher acquisition cost, there were no significant differences in total or outpatient costs between groups.

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech